BioBridgeX
ServicesVendorsResources

Clinical CRO & CDMO services

Phase 1 to 4 operations, data, biostatistics, and pharmacovigilance. Source and compare qualified suppliers on BioBridgeX, and contract directly with the supplier you choose. Free for buyers.

Quick answer

The Clinical stage is running a drug through human trials, Phase 1 through Phase 4. Buyers source CROs and specialist suppliers for clinical operations, a Phase 1 unit, data management, biostatistics, medical writing, pharmacovigilance, a central lab, clinical supply, and real-world evidence. On BioBridgeX, sponsors compare qualified, GCP-compliant suppliers across any indication or modality and contract once, free to the buyer.

Clinical service categories

Clinical Operations
Phase 1 / Early Clinical Unit
Clinical Data Management
Biostatistics & Statistical Programming
Medical Writing
Pharmacovigilance & Drug Safety
Central Laboratory Services
Clinical Trial Supply & Logistics
Real-World Evidence & Epidemiology

What is the clinical stage in drug development?

The clinical stage is where a candidate that cleared its IND-enabling work finally meets patients. It runs from first-in-human dosing through post-approval studies, and it is conventionally split into Phase 1 (safety and dose), Phase 2 (early efficacy and dose-finding), Phase 3 (the pivotal data behind an NDA or BLA), and Phase 4 (post-marketing commitments and label expansion). On the BioBridgeX grid these sit under one Clinical stage, but the work behind each phase differs enough that sponsors usually assemble a different set of suppliers as the program grows.

This is the most expensive and most operationally demanding part of development. A Phase 1 study might enroll a few dozen healthy volunteers at a single unit over a few months. A global Phase 3 can run across many sites and countries for several years, generate an enormous volume of data, and carry hard timelines tied to a planned submission. The choices a sponsor makes here, full-service CRO versus functional outsourcing, where the data lives, who owns pharmacovigilance, shape cost, speed, and inspection-readiness for years.

Everything in this stage runs under Good Clinical Practice (GCP), the ICH E6 guideline. GCP is not paperwork for its own sake. It is the quality system that makes your data usable by the FDA, EMA, PMDA, or NMPA. A supplier that cannot show GCP-trained staff, validated systems, and a clean inspection history is a risk no matter how low the bid.

What CRO and CDMO services do you source at the clinical stage?

Clinical is mostly a CRO and specialist-services stage, with the manufacturing-adjacent piece (clinical trial material supply) sitting on the CDMO side. Sponsors buy these as a bundled full-service package or as separate functional units, depending on how much they can run in-house.

Buyers on BioBridgeX source these clinical service categories:

  • Clinical Operations: site identification and feasibility, study startup, CRA monitoring (on-site, remote, and risk-based), project management, and trial master file oversight. This is the spine of any trial.
  • Phase 1 / Early Clinical Unit: dedicated early-phase facilities with beds, telemetry, and on-site PK sampling for first-in-human work, SAD and MAD dose escalation, food-effect, and bioequivalence studies.
  • Clinical Data Management: EDC build (Medidata Rave, Veeva CDMS, OpenClinica), CRF and edit-check design, data cleaning, query management, and database lock, increasingly delivered CDISC SDTM and ADaM conformant from the start.
  • Biostatistics and Statistical Programming: the statistical analysis plan, randomization schedules, sample size and power calculations, interim analyses, DSMB support, and the SAS or R programming behind tables, listings, and figures.
  • Medical Writing: protocols, investigator brochures, informed consent forms, clinical study reports (ICH E3), and the clinical modules of a submission dossier.
  • Pharmacovigilance and Drug Safety: SAE intake and case processing, MedDRA coding, expedited reporting (E2B ICSRs to the FDA and EMA), aggregate reports (DSUR, PBRER), signal detection, and safety database management.
  • Central Laboratory Services: one lab analyzing samples from every site, with kit logistics, sample tracking, and harmonized reference ranges so results stay comparable across the whole trial.
  • Clinical Trial Supply and Logistics: IMP packaging, labeling, blinding, IRT and RTSM randomization, cold-chain distribution, and depot management. This crosses into CDMO territory.
  • Real-World Evidence and Epidemiology: registry studies, claims and EHR analyses, external control arms, and post-marketing observational work supporting Phase 4 and HEOR.

Should I use a full-service CRO or functional service providers?

This is the central make-or-buy call at the clinical stage, and the answer turns on your internal capability and program scale. A full-service CRO runs the whole trial under one master service agreement: operations, data, stats, medical writing, and often pharmacovigilance. That single point of accountability is the draw for a small biotech with a lean clinical team. The trade-off is less granular control and the risk of paying for capacity you do not need.

Functional service provider (FSP) outsourcing keeps the sponsor as the integrator and contracts out specific functions: biostatistics and data management to one supplier, monitoring to another, pharmacovigilance to a specialist. Larger sponsors and those with strong in-house clinical leadership often prefer FSP because it preserves oversight and lets them pick the best supplier per function. The cost is coordination overhead, which lands on the sponsor.

When you compare suppliers, look past the headline rate. The questions that actually predict a clean trial: how much therapeutic-area and indication experience does the team have in your specific disease? Who are the named CRAs and the project lead, not just the company logo? What is their inspection and audit history? How do they handle data transfer and CDISC standards? Can they staff your geographies? A supplier that is strong in oncology Phase 3 can be the wrong choice for a small rare-disease Phase 2 spread thinly across many countries.

How long does a clinical trial take, and what drives the budget?

Timelines at this stage are driven by enrollment, not by how hard a supplier works. A first-in-human Phase 1 at a dedicated unit can read out within months once dosing starts. Phase 2 typically runs one to two years. Pivotal Phase 3 trials commonly span several years from first-patient-in to database lock, and that back half is the part most programs underestimate, because slow enrollment, not study conduct, is the usual culprit.

Pin down a few scope items early. Study startup (contracts, IRB or IEC and regulatory approvals, site activation) is its own multi-month block before a single patient enrolls. The path from database lock to topline results, then to a final clinical study report, adds weeks to months on the back end. Pharmacovigilance and the safety database need to be live before first dose, not retrofitted later. Clinical supply lead times for IMP packaging and labeling have to be scheduled backward from site activation, especially for cold-chain or blinded product.

Budget structure matters as much as the headline number. Most CRO contracts separate direct fees (the supplier's labor) from pass-through costs and investigator grants, which often dwarf the fees on a large trial. A bid that looks cheap on direct fees can turn expensive once site payments and pass-throughs load in. Ask for a unit-cost breakdown and a change-order policy up front, because protocol amendments are close to inevitable and they are where budgets quietly blow out.

What quality and compliance standards apply at the clinical stage?

Good Clinical Practice (GCP) is the governing standard for trial conduct, built on ICH E6(R2), with E6(R3) now finalized. It covers informed consent, investigator responsibilities, monitoring, source data verification, and the integrity of the trial master file. Any supplier touching patient data or study conduct should run a GCP-compliant quality system, and you should expect to audit it.

The clinical and manufacturing standards interlock. Investigational product is made under Good Manufacturing Practice (GMP), so your clinical supply and any drug product carried over from CMC stay under GMP even while the trial itself runs under GCP. Bioanalytical and central lab work that supports regulatory decisions is expected to follow Good Laboratory Practice (GLP) or GCLP conventions with validated methods. When a sponsor buys across these functions, matching the right standard to each piece of work is part of the diligence.

Data standards are effectively mandatory for US and major-market submissions. The FDA requires CDISC-conformant datasets, SDTM for collected data and ADaM for analysis, so build your EDC and statistical programming to those standards from day one rather than remediating at submission. Region matters too: a supplier's track record with FDA, EMA, PMDA, or NMPA inspections tells you whether your data will hold up where you plan to file. On BioBridgeX, compliance attributes (GLP, GMP, GCP) and regulatory region are filterable, so you can screen for the standards your program actually needs.

How does sourcing clinical CRO and CDMO services through BioBridgeX work?

BioBridgeX is a neutral marketplace, not a CRO and not an agent for any supplier. You give us the scope (phase, indication, modality, geographies, and which of the nine clinical functions you need), and you get matched with qualified suppliers who can actually do the work. You compare them side by side, request quotes, and shortlist. Sourcing on the platform is free for buyers.

The structural advantage is contracting. Instead of separately negotiating master service agreements with a clin-ops CRO, a biostatistics FSP, a pharmacovigilance specialist, and a clinical supply supplier, you compare quotes and contract directly with the suppliers you choose, in one place through BioBridgeX. BioBridgeX acts as the marketplace. That takes weeks of parallel legal and procurement work off the table, work that at the clinical stage often sits on the critical path before startup.

The model is simple and the incentives line up. Buyers pay nothing. Suppliers pay a flat 2 percent fee, so there is no reason to steer you toward a pricier provider. Coverage spans every indication and modality, from small molecules to ADCs, gene and cell therapies, and oligonucleotides, so a rare-disease cell therapy sponsor and an oncology small-molecule sponsor draw from the same neutral pool of vetted suppliers.

Frequently asked questions

What is the difference between a CRO and a CDMO at the clinical stage?
A CRO (Contract Research Organization) runs the trial: operations, monitoring, data management, biostatistics, medical writing, and pharmacovigilance. A CDMO (Contract Development and Manufacturing Organization) makes the drug. At the clinical stage almost all the services are CRO work; the CDMO overlap is clinical trial supply, where investigational product is manufactured, packaged, labeled, and shipped to sites under GMP. BioBridgeX lets you source both sides in one place and contract directly with each supplier you choose.
Do I need a full-service CRO or can I outsource clinical functions separately?
Both models work. A full-service CRO runs the entire trial under one agreement, which suits small biotechs with lean clinical teams. Functional service provider (FSP) outsourcing contracts out individual functions like biostatistics or pharmacovigilance while the sponsor stays the integrator, which suits larger sponsors that want to keep oversight and pick the best supplier per function. The right answer depends on your in-house capability and how many studies you run at once.
What does Good Clinical Practice (GCP) require of a clinical supplier?
GCP, defined by ICH E6, is the quality standard for designing, conducting, and reporting trials. A compliant supplier needs GCP-trained staff, validated systems (EDC, safety database, IRT), documented SOPs, sound informed consent handling, and a clean audit and inspection history. GCP is what makes your data acceptable to the FDA, EMA, PMDA, and NMPA. Verify a supplier's GCP posture before contracting, and expect to audit it.
How long does a clinical trial take?
It varies by phase and is driven mostly by enrollment. A Phase 1 unit study can read out within months of first dose. Phase 2 typically runs one to two years. Pivotal Phase 3 trials commonly run several years from first-patient-in to database lock. Add study startup (contracts, ethics and regulatory approvals, site activation) on the front end and clinical study reporting on the back end. Slow enrollment, not study conduct, is the most common cause of delay.
What is CDISC and why does it matter when choosing a data management supplier?
CDISC is the data standard the FDA requires for submission datasets: SDTM for collected data and ADaM for analysis data. If your EDC build and statistical programming follow CDISC from the start, the submission package assembles cleanly. If they do not, you face costly remediation before filing. When comparing clinical data management and biostatistics suppliers, confirm they deliver CDISC-conformant SDTM and ADaM as standard, not as an add-on.
When do I need to set up pharmacovigilance for my trial?
Before first dose. The safety database, SAE intake process, MedDRA coding, and expedited reporting workflows (ICSRs to the FDA and EMA) must be live the moment a patient receives study drug, because serious adverse event reporting timelines are strict and start immediately. Pharmacovigilance is not something to retrofit mid-trial. You can source it inside a full-service CRO bundle or as a standalone specialist function on BioBridgeX.
How much does it cost to use BioBridgeX as a clinical trial sponsor?
Nothing. Sourcing, matching, and comparing clinical CRO and CDMO suppliers is free for buyers. Suppliers pay a flat 2 percent fee on work booked through the platform. Because BioBridgeX is a neutral marketplace and the fee is flat, there is no reason to steer you toward a more expensive provider. You compare quotes and contract directly with each supplier on your program, all in one place.
Can BioBridgeX source clinical suppliers for any indication or modality?
Yes. Coverage spans all therapeutic areas (oncology, rare disease, CNS, immunology, infectious disease, and more) and all modalities, from small molecules and monoclonal antibodies to ADCs, gene and cell therapies, mRNA, and oligonucleotides. You filter by phase, indication, modality, geography, and compliance attributes (GCP, GMP, GLP), then compare the qualified suppliers that match your program.
What is a central lab and do I need one for my trial?
A central laboratory analyzes all biological samples from every trial site in one place, instead of each site using its own local lab. That gives harmonized reference ranges and comparable results across the whole study, which matters for multi-site and multi-country trials. The central lab also handles sample kit logistics and tracking. Most Phase 2 and Phase 3 trials use one; small single-site Phase 1 studies sometimes rely on the unit's own lab.
What is real-world evidence and when is it used in clinical development?
Real-world evidence (RWE) uses data from outside randomized trials: registries, insurance claims, and electronic health records. In clinical development it supports external control arms (a comparator built from real-world data rather than a placebo group), Phase 4 post-marketing studies, and health economics and outcomes research (HEOR) for payers. It comes up often in rare disease, where a traditional control arm is impractical. RWE and epidemiology suppliers are sourceable as a clinical service category on BioBridgeX.

Source Clinical with one contract

Compare transparent quotes from qualified Clinical CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes